China Regenerative Medicine International Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for China Regenerative Medicine International.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 42.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding
Mar 05
China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%
Jan 04These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet
Jun 11Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year
Mar 16What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?
Feb 08Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares
Dec 15
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)
Nov 25Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Regenerative Medicine International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 55 | -104 | 6 | 6 | N/A |
| 3/31/2024 | 45 | -101 | N/A | N/A | N/A |
| 12/31/2023 | 69 | -108 | 6 | 6 | N/A |
| 9/30/2023 | -35 | 1 | N/A | N/A | N/A |
| 6/30/2023 | 29 | 15 | -5 | -2 | N/A |
| 3/31/2023 | 234 | 5 | N/A | N/A | N/A |
| 12/31/2022 | 42 | 5 | -15 | -12 | N/A |
| 9/30/2022 | 246 | 31 | N/A | N/A | N/A |
| 6/30/2022 | 254 | 26 | -5 | -5 | N/A |
| 3/31/2022 | 294 | 49 | N/A | N/A | N/A |
| 12/31/2021 | 283 | 52 | -4 | -3 | N/A |
| 9/30/2021 | 274 | -95 | N/A | N/A | N/A |
| 6/30/2021 | 248 | -82 | -122 | -122 | N/A |
| 3/31/2021 | 222 | -105 | N/A | N/A | N/A |
| 12/31/2020 | 182 | -120 | -399 | -399 | N/A |
| 9/30/2020 | 110 | -201 | N/A | N/A | N/A |
| 6/30/2020 | 57 | -237 | -324 | -319 | N/A |
| 3/31/2020 | 12 | -239 | N/A | N/A | N/A |
| 12/31/2019 | 19 | -264 | -29 | -23 | N/A |
| 9/30/2019 | 15 | -1,005 | N/A | N/A | N/A |
| 6/30/2019 | 19 | -1,042 | 34 | 48 | N/A |
| 3/31/2019 | 56 | -1,177 | N/A | N/A | N/A |
| 12/31/2018 | 73 | -1,194 | 6 | 19 | N/A |
| 9/30/2018 | 555 | -346 | N/A | N/A | N/A |
| 6/30/2018 | 607 | -337 | -183 | -169 | N/A |
| 3/31/2018 | 642 | -237 | N/A | N/A | N/A |
| 12/31/2017 | 756 | -238 | N/A | -290 | N/A |
| 10/31/2017 | 489 | -171 | N/A | -121 | N/A |
| 7/30/2017 | 425 | -169 | N/A | N/A | N/A |
| 4/30/2017 | 357 | -185 | N/A | -461 | N/A |
| 1/31/2017 | 284 | -182 | N/A | N/A | N/A |
| 10/31/2016 | 51 | -261 | N/A | -403 | N/A |
| 7/31/2016 | 29 | -223 | N/A | N/A | N/A |
| 4/30/2016 | 28 | -191 | N/A | -99 | N/A |
| 1/31/2016 | 18 | -269 | N/A | N/A | N/A |
| 10/31/2015 | 6 | -243 | N/A | -317 | N/A |
| 7/31/2015 | 4 | -259 | N/A | N/A | N/A |
| 4/30/2015 | 3 | -250 | N/A | -218 | N/A |
| 1/31/2015 | 2 | -299 | N/A | N/A | N/A |
| 10/31/2014 | 2 | -292 | N/A | -103 | N/A |
| 7/31/2014 | 1 | -281 | N/A | N/A | N/A |
| 4/30/2014 | 1 | -263 | N/A | -126 | N/A |
| 1/31/2014 | 0 | -103 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 8158's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 8158's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 8158's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 8158's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 8158's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8158's Return on Equity is forecast to be high in 3 years time